More than 33 Percent of Americans Refuse
The Best Colorectal Cancer Test is the Test That Gets Done
|
ColonSentry® is a proprietary liquid biopsy test that uses advanced gene expression (mRNA) technology for the early identification of Colorectal Cancer (CRC). ColonSentry requires a simple, in-office blood draw. If the ColonSentry score is elevated in a patient at average risk, there is an increased probability the patient may have a pre-cancerous lesion or colorectal cancer.¹ ²
Studies have shown 80-95% of patients who refuse Colonoscopy will comply with a blood test. Following a ColonSentry test result, patients are two-times more likely to comply with Colonoscopy.
|
|
Physicians
If you are physician, click the Order Test button below to begin offering this test to patients in your practice.
|
Patients
You can initiate an order through our physician network by clicking the order test button below or calling 855-420-7140
The ColonSentry test needs to be ordered by a physician. Download our Patient/Physician Discussion Guide to take to your next appointment.
|
ColonSentry Patient Selection Criteria
The American Cancer Society recommends that people at average risk of colorectal cancer start regular screening at age 45. ³
Patients may candidate for the ColonSentry Test if they are
The American Cancer Society recommends that people at average risk of colorectal cancer start regular screening at age 45. ³
Patients may candidate for the ColonSentry Test if they are
- Age 45 of older and at average risk for Colorectal Cancer
- Are without symptoms such as bleeding, abdominal pain, or change in bowel habits.
- Have not had a Colonoscopy or Stool-Based Screening Test
References
- Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006 Mar;147(3):126-32.
- Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010 Mar 1;126(5):1177-86.
- American Cancer Society. Guideline for Colorectal Cancer Screening. Last revised May 30, 2018.
- Chao S, Ying J, Liew G, et al. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case- control study. J Exp Clin Cancer Res. 2013 Jul 23;32:44.
- Yip KT, Das PK, Suria D, et al. A case- controlled validation study of a blood- based seven-gene biomarker panel for colorectal cancer in Malaysia. J Exp Clin Cancer Res. 2010 Sep 16;29:128
- Han M, Liew CT, Zhang HW, et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res. 2008 Jan 15;14(2):455-60.
- Moghadamyeghaneh Z, Alizadeh RF, Phelan M, et al. Trends in Colorectal Cancer Admissions and Stage at Presentation-Impact of Screening. Surgical endoscopy. 2016;30(8):3604-3610. doi:10.1007/s00464-015-4662-3.
- * Data on file
